Invicta Medical

Executive Summary

Invicta Medical, operating under the brand Restera, is a private medical device and digital health company headquartered in San Francisco. Founded in 2015, the company has assembled a world-class team of clinicians, engineers, and investors with a singular mission: to deliver a transformative treatment for Obstructive Sleep Apnea (OSA). Restera's approach aims to address the limitations of current therapies, such as CPAP machines, by offering a novel, non-invasive solution that improves patient compliance and outcomes. The company is currently in Phase 1 development, focusing on preclinical or early clinical validation of its technology. While specific financial and operational details remain undisclosed, Invicta's strong collaborative network with leading research institutions underscores its potential to disrupt the large and growing OSA treatment market, which affects an estimated 1 billion people worldwide. The success of Restera's platform could significantly enhance quality of life for patients and reduce healthcare costs associated with untreated sleep apnea. Given the early stage, investment carries high risk but also substantial upside if the technology proves effective and achieves regulatory clearance.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 Clinical Trial Initiation or Results40% success
• Q2 2026FDA Investigational Device Exemption (IDE) Approval50% success
• Q3 2026Strategic Partnership or Licensing Agreement with Major Sleep or Respiratory Company30% success